IMPAX Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for a generic version of Wellbutrin® XL 150 mg Extended-release Tablets on Wednesday, November 26, 2008. GlaxoSmithKline markets Wellbutrin® XL for the management of depression. IMPAX’s Global Pharmaceuticals division launched the product immediately following approval.
Popularity: unranked [?]
Related posts:
- Actavis Receives Approval Of Generic Wellbutrin XL(R) 300mg In The United States
- Biovail Receives Canadian Approval For Wellbutrin(R) XL For The Prevention Of Seasonal Major Depressive Illness
- Barr Receives Tentative Approval For A Generic Version Of ZYPREXA(R) Zydis(R) Tablets, 5mg, 10mg, 15mg And 20mg
- Biovail Receives FDA Approval For Aplenzin (BVF-033) For The Treatment Of Depression
- Par Pharmaceutical Receives Final Approval To Market Tranylcypromine Sulfate Tablets
Comments
No Responses to “IMPAX Receives Final FDA Approval For Generic Wellbutrin(R) XL 150 Mg”